Trial Profile
Comparison to investigate incidence of adverse events between lenalidomide, bortezomib, thalidomide and other approved treatments for the treatment of relapsed/refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 15 Dec 2015 New trial record